Conventional chemotherapy vs ASCT
| Ref. . | Year . | Treatment arms . | Overall response (chemotherapy vs ASCT) . | PFS (chemotherapy vs ASCT) . | OS (chemotherapy vs ASCT) . |
|---|---|---|---|---|---|
| Attal et al9 | 1996 | Alternating cycles of VMCP/BVAP × 18 cycles vs same regimen × 4-6 cycles followed by ASCT | 57% vs 81% (P < .01) | 5 y: 10% vs 28% (P = .01) | 5 y: 52% vs 12% (P = .03) |
| Child et al10 | 2003 | ABCM × 4-12 cycles vs doxorubicin, cyclophosphamide, and prednisone × 3 cycles followed by ASCT | CR: 8% vs 44% (P < .01) | 19.6 mo vs 31.6 mo (P < .01) | 42.3 mo vs 54.1 mo (P = .04) |
| Bladé et al51 | 2005 | Alternating cycles of VBMCP/VBAD followed by VBMCP/VBAD × 8 cycles vs ASCT | CR: 11% vs 30% (P < .01) | 33 mo vs 42 mo (P = NS) | 66 mo vs 61 mo (P = NS) |
| Fermand et al52 | 2005 | VMCP until plateau vs VAMP × 3-4 cycles and ASCT | CR: 20% vs 36% | 19 mo vs 25 mo (P = .07) | 47.6 mp vs 47.8 mo (P = .91) |
| Barlogie et al11 | 2006 | VAD × 4 cycles and VBMCP vs VAD × 4 cycles and ASCT with/without IFN maintenance | 7 y: 16% vs 17% (P = NS) | 7 y: 42% vs 37% (P = NS) | |
| Palumbo et al14 | 2014 | RD × 4 cycles and MPR × 6 cycles vs RD × 4 cycles and ASCT with/without R maintenance | 22.4 mo vs 43 mo (P < .001) | 4 y: 65.3% vs 81.6% (P = .02) | |
| Gay et al15 | 2015 | RD × 4 cycles and RCD × 6 cycles vs RD × 4 cycles and ASCT with/without R maintenance | 28.6 mo vs 43.3 mo (P < .0001) | 4 y: 73% vs 86% (P = .004) |
| Ref. . | Year . | Treatment arms . | Overall response (chemotherapy vs ASCT) . | PFS (chemotherapy vs ASCT) . | OS (chemotherapy vs ASCT) . |
|---|---|---|---|---|---|
| Attal et al9 | 1996 | Alternating cycles of VMCP/BVAP × 18 cycles vs same regimen × 4-6 cycles followed by ASCT | 57% vs 81% (P < .01) | 5 y: 10% vs 28% (P = .01) | 5 y: 52% vs 12% (P = .03) |
| Child et al10 | 2003 | ABCM × 4-12 cycles vs doxorubicin, cyclophosphamide, and prednisone × 3 cycles followed by ASCT | CR: 8% vs 44% (P < .01) | 19.6 mo vs 31.6 mo (P < .01) | 42.3 mo vs 54.1 mo (P = .04) |
| Bladé et al51 | 2005 | Alternating cycles of VBMCP/VBAD followed by VBMCP/VBAD × 8 cycles vs ASCT | CR: 11% vs 30% (P < .01) | 33 mo vs 42 mo (P = NS) | 66 mo vs 61 mo (P = NS) |
| Fermand et al52 | 2005 | VMCP until plateau vs VAMP × 3-4 cycles and ASCT | CR: 20% vs 36% | 19 mo vs 25 mo (P = .07) | 47.6 mp vs 47.8 mo (P = .91) |
| Barlogie et al11 | 2006 | VAD × 4 cycles and VBMCP vs VAD × 4 cycles and ASCT with/without IFN maintenance | 7 y: 16% vs 17% (P = NS) | 7 y: 42% vs 37% (P = NS) | |
| Palumbo et al14 | 2014 | RD × 4 cycles and MPR × 6 cycles vs RD × 4 cycles and ASCT with/without R maintenance | 22.4 mo vs 43 mo (P < .001) | 4 y: 65.3% vs 81.6% (P = .02) | |
| Gay et al15 | 2015 | RD × 4 cycles and RCD × 6 cycles vs RD × 4 cycles and ASCT with/without R maintenance | 28.6 mo vs 43.3 mo (P < .0001) | 4 y: 73% vs 86% (P = .004) |
ABCM, adriamycin; BCNU, cyclophosphamide and melphalan; BVAP, BCNU, vincristine, adriamycin, prednisone; CR, complete response; IFN, interferon; MPR, melphalan, prednisolone, Revlimid; NS, nonsignificant; R, Revlimid; RCD, Revlimid, cyclophosphamide, dexamethasone; RD, Revlimid, dexamethasone; Ref., reference; VAD, vincristine, Adriamycin, dexamethasone; VAMP, vincristine, Adriamycin, melphalan, prednisolone; VBAD, vincristine, BCNU, Adriamycin, dexamethasone; VMCP; vincristine, melphalan, cyclophosphamide, prednisolone; VBMCP, vincristine, BCNU, melphalan, cyclophosphamide, prednisolone.